In the trial, researchers focused on reducing HbA1c, a blood test that reflects average blood sugar levels over three months, The Independent reported. From a baseline average HbA1c of 8.3 percent, orforglipron reduced this value by an average of 1.71 to 1.91 percent after 52 weeks, according to the same source. In comparison, oral semaglutide reduced HbA1c by 1.47 percent over the same period, The Independent noted. Participants who took orforglipron also lost an average of 6.1 to 8.2 kilograms in weight after 52 weeks, The Independent reported. These results suggest orforglipron may offer a more potent alternative for managing type 2 diabetes and obesity.
Existing GLP-1 medications, such as injectable semaglutide sold under brand names like Wegovy and Ozempic, mimic the gut hormone GLP-1 to signal fullness to the brain, slow digestion, and stimulate insulin release, according to The Independent. However, a key issue with injectable semaglutide is that it requires injection into the belly, thighs, or back of the arm, which can be difficult for patients with needle phobia or inconvenience, The Independent noted. Another logistical challenge with injectable GLP-1 drugs is their need for refrigeration throughout the supply chain, posing difficulties in low- and middle-income countries, The Independent reported.
Oral semaglutide, while avoiding injections, comes with its own limitations. According to The Independent, it must be taken on an empty stomach, and users must wait 30 minutes before eating or drinking. Additionally, oral semaglutide has poor bioavailability, with only about 1 percent of the ingested drug absorbed and able to exert its effects, The Independent noted. These factors can reduce adherence and effectiveness in real-world settings.
Clinical context for interpreting the HbA1c results is important, as diabetes is typically diagnosed when HbA1c levels reach 6.5 percent or more, The Independent reported. The reductions seen with orforglipron and oral semaglutide indicate significant improvements in blood sugar control, potentially helping patients achieve healthier ranges. However, the specific safety profile of orforglipron compared to oral semaglutide remains unclear, and its side effects have not been detailed in the available reports. Key unknowns include when orforglipron is expected to be approved and available on the market, as well as its cost compared to existing oral and injectable weight-loss drugs. Further details, such as how orforglipron's bioavailability compares to that of oral semaglutide and the specific countries involved in the phase 3 trial, are also not yet confirmed.